Point mutations of ras oncogenes are an early event in thyroid tumorigenesis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Understanding genetic mutations in thyroid neoplasms is crucial for elucidating tumor pathogenesis.
• Ras oncogenes are frequently activated in human tumors via point mutations in specific functional regions.
• Codons 12, 13 (GTP-binding domain) and 61 (GTPase domain) are key sites for ras oncogene mutations.

Purpose of the Study:

• To determine the prevalence of point mutations in codons 12, 13, and 61 of K-ras, N-ras, and H-ras oncogenes.
• To investigate the association of ras mutations with different thyroid tumor phenotypes (benign and malignant).
• To assess whether ras activation is an early event in thyroid tumorigenesis.

Main Methods:

• Polymerase chain reaction (PCR) amplification of tumor DNA from thyroid tissues.
• Hybridization of amplified DNA with synthetic oligodeoxynucleotide probes to detect point mutations.
• DNA sequencing to confirm specific mutations, particularly in monoclonal adenomas.

Main Results:

• No ras point mutations were detected in normal thyroid tissues.
• Ras mutations were found in 21% of multinodular goiter nodules, 25% of microfollicular adenomas, and 21% of papillary carcinomas.
• Follicular carcinomas showed no ras mutations in this study; the predominant mutation involved H-ras codon 12.

Conclusions:

• Ras gene activation occurs at a similar frequency in benign and malignant thyroid neoplasms.
• Ras mutations may represent an early event in the development of thyroid tumors.
• The findings contribute to understanding the genetic landscape of thyroid neoplasia.